Replimune Group, Inc. (REPL) Misses Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. FIX
9. TSCO
10. BE

Go back to Replimune Group, Inc. (REPL) Misses Q2 EPS by 5c

Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

November 3, 2022 8:00 AM EDT

Completed enrollment in the CERPASS registration-directed clinical trial evaluating RP1 in cutaneous squamous cell carcinoma (CSCC); primary analysis data expected to be released in H1 2023

Six-month follow-up data from the first 75 patients enrolled in the IGNYTE clinical trial cohort of RP1 combined with Opdivo® (nivolumab) in anti-PD1 failed melanoma expected by year end

An update on the RP2/3 development program remains on track to be provided by year end

Completed $200 million term-loan that extended cash runway into 2025

WOBURN, Mass., Nov. 03,... More